Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers
This Viewpoint discusses recommendations for angiotensin-converting enzyme inhibitor and angiotensin receptor blocker use in patients with or at risk of contracting coronavirus disease 2019 (COVID-19).
Source:
JAMA Cardiology
SPS commentary:
The review describes guidance available from the various Cardiovascular societies around the world, and in summary, all guidelines recommend continuing ACEIs/ARBs in patients with COVID-19 unless clinically indicated. Furthermore, none suggest initiation of ACEIs/ARBs in those without another clinical indication (e.g. hypertension, heart failure, diabetes), given the lack of strong evidence showing benefit of these medications in COVID-19.